Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model.
This announcement marks a significant milestone for the clinical-stage precision oncology company as it transitions from a purely drug-development focus to also offering AI-driven research tools to the broader biomedical community. The withZeta.ai platform, which is now commercially available as a subscription-based research platform, represents a new revenue stream for Lantern. By enabling researchers to harness multi-agentic AI to analyze complex datasets, the platform could reduce the time and cost associated with early-stage drug discovery, potentially reshaping how oncology therapies are developed.
The implications for the industry are substantial. Traditional drug discovery is notoriously slow and expensive, with many candidates failing in clinical trials. AI-driven platforms like withZeta.ai aim to streamline the process by identifying promising drug candidates and biomarkers more efficiently. For patients, especially those with rare cancers that often lack effective treatments, this could mean faster access to novel therapies. For Lantern, the shift to a subscription model offers recurring revenue and positions the company at the intersection of AI and biotech, a rapidly growing sector.
Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The live demonstration is expected to provide investors and researchers with a firsthand look at the platform’s capabilities. To view the full press release, visit https://ibn.fm/wzevl. For the latest news and updates relating to LTRN, visit the company’s newsroom at https://ibn.fm/LTRN.
